Comaneci™ temporarily expands blood vessels–recognized as novel device for life-threatening disease

YOKNEAM, Israel & MIAMI–(BUSINESS WIRE)–#COMANECIRapid Medical, a leading developer of advanced neurovascular devices, today announced FDA breakthrough designation for its Comaneci™ embolization assist device to facilitate the treatment of cerebral vasospasm following hemorrhagic stroke. Vasospasm is a major complication and cause of morbidity. The FDA’s Breakthrough Device Program is designed to give patients more timely access to novel technologies, like Comaneci, that provide more effective treatments for life-threatening or irreversibly debilitating human diseases and conditions.

“We just need better solutions for patients–no single treatment has been shown to be uniformly safe and effective in treating symptomatic vasospasm,” comments Brian Jankowitz, MD, a neurosurgeon at the University of Pennsylvania. “Comaneci is the first device to provide combination therapy to the brain with an adjustable diameter/radial force that may lower the risk of vessel injury.”

Comaneci, available in Europe for vasospasm intervention, is showing promising results. In a 30-patient multi-center retrospective analysis, 97% of patients showed an increase in vessel opening of at least 25%, with 80% of patients showing an increase of 50% or more1. Additionally, over 10,000 procedures have been performed world-wide utilizing Comaneci to assist in the coil embolization of wide-neck intracranial aneurysms. Comaneci’s adjustable diameter, low delivery profile and excellent visibility have drawn physicians around the globe to demand Comaneci. As a temporary device, it offers a treatment modality that may prevent the need for permanent devices implanted in the brain.

Cerebral vasospasm is a devastating complication of subarachnoid hemorrhage. The spasms cause a narrowing of the brain blood vessels, reducing blood flow and leading to the death of brain tissue. This occurs in 70% of patients and leads to neurological deterioration in up to 30%2.

“This breakthrough designation will help expedite the availability of Comaneci, potentially providing a safer option for these sick patients, describes James Romero, President, Americas, at Rapid Medical. “It underscores how we pioneer tools that provide physicians with greater control and expand treatment options tailored to patients.”

About Rapid Medical

Rapid Medical develops the premier, responsive interventional devices for neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER™17 and 21, COMANECI™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER™13 and XL are also CE marked. More information is available at

1 Data on file at Rapid Medical from centers in Germany, Spain, Switzerland, France and USA.

2 Shaikh el at; Treatment of cerebral vasospasm secondary to subarachnoid hemorrhage utilizing the Comaneci device. International Neuroradiology, June 2020


Ronen Eckhouse


Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.